Acelyrin has shared positive results from a late-stage study of its IL-17A inhibitor izokibep in hidradenitis suppurativa (HS), but has said it will not be moving forward with the asset in this indication.
Estimated to affect about 1% of the population in most studied countries, HS is a chronic inflammatory skin condition that causes painful nodules and abscesses.
In the phase 3 trial, izokibep demonstrated statistically significant responses across multiple efficacy endpoints at week 12, with 33% of patients being treated with izokibep 160mg weekly achieving at least a 75% reduction in total abscess and inflammatory nodule count (HiSCR75) compared to 21% of those receiving placebo.
Results also showed that 25% and 22% of izokibep-treated patients achieved HiSCR90 and HiSCR100, respectively, compared to 9% and 8% in the placebo cohort.
The announcement comes shortly after the drug demonstrated promising results in a phase 2b/3 study for psoriatic arthritis (PsA), a chronic inflammatory disease characterised by joint pain, stiffness and swelling.
Acelyrin said it will complete the ongoing HS and PsA trials, but will suspend new investment in these indications. A phase 2b/3 trial of izokibep in uveitis will also continue through its primary endpoint, with top-line data expected later this year.
The company outlined that it will now be prioritising the development of lonigutamab, an anti-IGF-1R monoclonal antibody being evaluated as a treatment for thyroid eye disease (TED).

https://pharmatimes.com/news/acelyrins-izokibep-for-hidradenitis-suppurativa-reveals-positive-results/